Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00080066" target="_blank" >RIV/00216224:14110/14:00080066 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002" target="_blank" >http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002" target="_blank" >10.3978/j.issn.2218-6751.2014.AB002</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Popis výsledku v původním jazyce
Background: Worldwide, lung cancer is the most common cause of cancer-related death, and was responsible for 1.56 million deaths annually, as of 2012. The situation in the Czech Republic is identical, lung cancer is the leading cause of mortality due tomalignant tumours, with 5,572 cancer related deaths in 2010. The detection of epidermal growth factor receptor (EGFR) gene mutations can guide targeted therapies for non-small cell lung cancer (NSCLC), because most of these mutations are strongly associated with clinical response to EGFR tyrosine kinase inhibitors. The aim of this study was to verify the frequency of EGFR mutations in a large group of Caucasians patients with advanced stage non-squamous NSCLC. Methods: Analysed data were collected in the period from November 15, 2011 to June 30, 2013 in three pneumo-oncological centres.
Název v anglickém jazyce
Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Popis výsledku anglicky
Background: Worldwide, lung cancer is the most common cause of cancer-related death, and was responsible for 1.56 million deaths annually, as of 2012. The situation in the Czech Republic is identical, lung cancer is the leading cause of mortality due tomalignant tumours, with 5,572 cancer related deaths in 2010. The detection of epidermal growth factor receptor (EGFR) gene mutations can guide targeted therapies for non-small cell lung cancer (NSCLC), because most of these mutations are strongly associated with clinical response to EGFR tyrosine kinase inhibitors. The aim of this study was to verify the frequency of EGFR mutations in a large group of Caucasians patients with advanced stage non-squamous NSCLC. Methods: Analysed data were collected in the period from November 15, 2011 to June 30, 2013 in three pneumo-oncological centres.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů